Natixis’s Avalo Therapeutics AVTX Stock Holding History
Bought
Maintained
Sold
Other funds holding AVTX
LGM
SCM
IC
AAA
CC
Natixis's AVTX Position: Q2 2024 in Review
Natixis sold out of Avalo Therapeutics (AVTX) in Q2 2024, closing a stake of 2,512 shares — an estimated $54.6K sold.
Natixis first reported a position in AVTX in Q4 2023 and held it in 2 quarters. The position peaked at $54.6K in Q1 2024. 21 funds tracked by Wall St. Rank hold AVTX as of Q2 2024.
- Natixis reported no remaining Avalo Therapeutics position as of Q2 2024 after selling out during the quarter.
- Natixis sold 2,512 Avalo Therapeutics shares in Q2 2024, an estimated $54.6K.
- Natixis first reported a position in Avalo Therapeutics in Q4 2023 and held it in 2 quarters.
- Natixis's Avalo Therapeutics position peaked at $54.6K in Q1 2024.
- 21 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2024.
Based on Natixis's 13F filing for Q2 2024, filed 13 Aug 2024.